Interview, Fireside Chat
a16z Podcast | On the Genomics of Disease, From Science to Business
- Human biology is recognized as significantly more complex than the 20,000-gene model suggests, necessitating new biological fields to interpret the 99.99% of the genome previously unexplored, while the dominance of current single-platform approaches faces potential disruption within 10 years.
- Genomics costs have plummeted from the $3 billion Human Genome Project to thousands or hundreds of dollars, following a trend that has exceeded Moore's Law by several magnitudes over the last decade.
- Computational capabilities, including DNA alignment tools reduced from days to five minutes and machine learning systems, now enable the processing of massive datasets to identify new biomarkers and interpret genomic data with increasing accuracy as more data is collected.
- Current cancer detection methods focusing on less than 1% of the genome have reached their limits, prompting a shift from symptomatic or risk-based testing (such as BRCA) to early, pre-symptomatic detection where survival rates can rise from less than 20% with chemotherapy to 80–97% with early identification.
- Therapeutic interventions currently offer a 30–40% five-year survival chance via immunotherapy, contrasting with prevention strategies that aim to systematize early detection for the entire population rather than relying on high-risk group testing or annual organ biopsies.
- The business environment is constrained by a three-party system where insurance companies often reject coverage for tests lacking a return on investment within a two-to-three-year window, despite genomic value materializing later, though single-payer systems may see faster adoption.
- Market dynamics include dominant hardware players like Illumina acquiring software applications (e.g., VariNata, Grail, Helix), while a "Wintel-style" partnership is viewed as necessary for industry growth, with Exact Sciences valued at approximately $2 billion and Asurix acquired by Myriad for half a billion dollars.
- Future innovation is anticipated to move toward home-based sequencing and mass spectrometry capabilities for sample collection via finger pricks or bathroom toilets, enabling new verticals in mental health and infectious disease while addressing spatial DNA orientation and cellular computing complexities.
- Challenges remain in defining early disease signatures and achieving sufficient accuracy and cost-efficiency to convince payers, while the industry is described as being at the very beginning of a computing revolution in biology with untold future health innovations.